Trial reportClinical drug investigation2012
Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility.
Trial report in Clinical drug investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA new tablet formulation of methadone was developed with unique physicochemical properties, allowing for decreased solubility in aqueous solutions in in vitro studies. It was unknown whether this newly developed formulation would affect its bioavailability compared with the currently available formulation of methadone.
objectivesThe objective of this study was to further examine the in vitro solubility of the new methadone formulation, and to evaluate and compare the relative bioavailability and pharmacokinetics to the previous reference formulation after a single oral dose administration under fasting conditions.
methodsIn vitro comparative dissolution for the new methadone formulation and the previous reference formulation was conducted. A randomized, single-dose, blinded, two-period, two-sequence, crossover pharmacokinetic study was performed in 24 healthy volunteers under fasting conditions.
resultsThe new methadone formulation demonstrated a 30-40% decrease in solubility over 30 minutes compared with the previous reference formulation at the highest dose; all other doses also showed decreased in vitro solubility. The pharmacokinetic parameters determined were: maximum plasma drug concentration (C(max)) of 38.1 ng/mL; time to reach C(max) (t(max)) of 2.80 hours; mean area under the plasma concentration-time curve (AUC) from time zero to 72 hours (AUC(72)) of 1043 ng · h/mL; mean AUC from time zero to infinity (AUC(∞)) of 1430 ng · h/mL; mean elimination rate constant (k(e)) of 0.0206 hours(-1); and mean elimination half-life (t(½)) of 36.7 hours. These values are statistically equivalent to the previous reference formulation of methadone.
conclusionThis study provides the first complete set of pharmacokinetic data on a novel methadone formulation. The formulation demonstrates decreased in vitro solubility while providing equivalent plasma methadone levels compared with the previous formulation.
Indexed as
Identifiers
22621465What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.